Insmed reported $725.8M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
DBV Technologies USD 6.1M 2.49M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 725.8M 1.82M Jun/2026
Novartis USD 47B 14.98B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026